Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847407 | 1.00 | KMT2A (0.56) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6265628 | 0.95 | RAB9A (0.52) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6220378 | 0.92 | KMT2A (0.53) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6219355 | 0.89 | RAB9A (0.50) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL5847699 | 0.89 | RAB9A (0.47) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL8348199 | 0.89 | RAB9A (0.50) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6218817 | 0.89 | RAB9A (0.47) | KMT2ANPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL7815155 | 0.87 | KMT2A (0.57) | KMT2ARAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8798443 | 0.87 | KMT2A (0.57) | KMT2ARAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5858099 | 0.87 | KMT2A (0.62) | KMT2ARAB9ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115596-B2 | Thiazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1572690-A1 | THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572691-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20050004200-A1 | Pyrazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-06 | — | — | US | disclosed |
| US-20050004189-A1 | Thiazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-06 | — | — | US | disclosed |
| WO-2004058761-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058761-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058760-A1 | THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | KMT2A 3592/4885NPC1 983/4885RAB9A 1213/4885 |
| US-20050004200-A1 | Pyrazole compounds as integrin receptor antagonists derivatives | ITGA5, ITGB3, ITGB5 | KMT2A 4015/4885NPC1 2030/4885RAB9A 814/4885 |
| US-20050004189-A1 | Thiazole compounds as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGAL | KMT2A 3963/4885NPC1 1297/4885RAB9A 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.